Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Difluprednate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Difluprednate is a topical corticosteroid for inflammation and pain associated with ocular surgery.It is thought to induce phospholipase A2 inhibitory proteins, which controls the biosynthesis of potent mediators of infammation by inhibiting the release ...
Product Name : Difluprednate-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
January 27, 2023
Lead Product(s) : Difluprednate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rose Bengal Sodium,Difluprednate,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Provectus Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Provectus Biopharmaceuticals Announces License Agreement for Antimicrobial Treatment
Details : Provectus will use the University’s PDAT medical device with RB-PDT for treating bacterial and parasitic infections of the eye.
Product Name : RB-PDT
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 27, 2024
Lead Product(s) : Rose Bengal Sodium,Difluprednate,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Provectus Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Difluprednate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cipla’s Difluprednate Ophthalmic Emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation’s Durezol®.
Product Name : Difluprednate-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
December 08, 2021
Lead Product(s) : Difluprednate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Difluprednate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
Details : Difluprednate Ophthalmic Emulsion,may result in posterior subcapsular cataract formation; increase the hazard of secondary ocular infections, and delay healing with the increase in the incidence of bleb formation.
Product Name : Difluprednate-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
November 19, 2021
Lead Product(s) : Difluprednate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable